Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | CALML3 | P27482 | 1/20 | 0.43 |
| ▸ | SDHA | P31040 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308013 | 0.87 | F10 (0.49) | F10F2 | |
| SCHEMBL6307450 | 0.86 | MAOA (0.43) | F10MAOBLMNAMAOAPTGS1 | |
| SCHEMBL6308957 | 0.85 | MAOB (0.55) | F10MAOBLMNAMAOAPTGS1 | |
| SCHEMBL6309326 | 0.84 | F10 (0.50) | F10F2MAOBLMNAMAOA | |
| SCHEMBL6309322 | 0.84 | F10 (0.48) | F10F2MAOBLMNAMAOA | |
| SCHEMBL5218235 | 0.84 | F10 (0.53) | F10F2MAOBLMNAMAOA | |
| SCHEMBL6308929 | 0.83 | MAOA (0.58) | F10F2MAOBLMNAMAOA | |
| SCHEMBL6314903 | 0.81 | MAOA (0.46) | F10MAOBLMNAMAOAPTGS1 | |
| SCHEMBL6306759 | 0.81 | F10 (0.49) | F10F2MAOBLMNAMAOA | |
| SCHEMBL6306773 | 0.81 | F10 (0.49) | F10F2MAOBLMNAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077626-A1 | Difluorothioacetamides of oxazolidinones as antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2004-04-22 | — | — | US | claimed |
| US-6927229-B2 | Difluorothioacetamides of oxazolidinones as antibacterial agents | PHARMACIA & UPJOHN COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| US-20040077626-A1 | Difluorothioacetamides of oxazolidinones as antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077626-A1 | Difluorothioacetamides of oxazolidinones as antibacterial agents | AADAC, DLAT, OXA1L | F10 4257/4885F2 4575/4885MAOB 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.